Andrx, die unentdeckte Perle - 500 Beiträge pro Seite

[Strand]

Merrill Lynch


Andrx "buy" Datum: 16.08.2001
Zeit: 10:04


Die Börsenspezialisten von Merrill Lynch empfehlen weiterhin, die Aktie des Pharmakonzerns Andrx Corp. zu kaufen. (WKN 565755) AstraZeneca habe beschlossen, dass man die Prilosec bezogenen aaiPharma Patente nicht zur Zulassung bei der FDA einreichen werde. Die Aktie von Andrx sollte aufgrund dieser Ankündigung positiv reagieren, da die Investoren bisher davon ausgegangen seien, dass die Patente angemeldet werden würden. Die Ankündigung von AstraZeneca würde allerdings nicht bedeuten, dass AstraZeneca keine anderen Mittel und Wege nutzen würde, um die Markteinführung für generisches Prilosec zu verzögern. Dennoch werde die Ankündigung von AstraZeneca als gutes Zeichen für Andrx beurteilt. Es sei wichtig zu erwähnen, dass die Rechtsstreitigkeiten der Unternehmen im Bereich des generischen Prilosec noch immer zu Richter Jones am Gericht von New York zurück transferiert werden müssten. Es sei möglich, dass AstraZeneca diese Rückverlegung herauszögern könnte, um den Beginn eines Prozesses heraus zu schieben. Trotz dieser Möglichkeiten habe man nichts am zeitlichen Ablauf für generisches Prilosec verändert, das basiere auf dem im Oktober oder November beginnenden Prozess und der im 1. Quartal 2001 von Richter Jones getroffenen Entscheidung. Prilosec sei nicht der einzige Grund, warum man den Kauf der Aktie empfehle. Große Auswirkungen durch dieses Präparat würden nur etwa 2. Quartale lang erwartet. In den kommenden Quartalen erwarte man ein weiteres Wachstum für Albuterol und nach der Zustimmung durch die FDA und die Markteinführung später in diesem Jahr auch für Glucophage. Nach Meinung der Aktienspezialisten sei das Risiko/Chanceverhältnis der Aktie weiterhin positiv. Die Aktie werde gegenwärtig mit dem 17-fachen der EPS Erwartung für 2002 (inklusive Prilosec) und dem 30-fachen dieser Erwartung ohne Prilosec gehandelt. Darüber hinaus verfüge das Unternehmen über eine solide generische Pipeline, eine gute Technologie und eine sehr gute Durchführung von strategischen Entscheidungen. Gegenwärtig liege die Erwartung für den Gewinn pro Aktie der Jahre 2001 und 2002 bei 1,29 und 3,50 US-Dollar. Die Erwartung des Börsenkonsens liege bei 1,48 und 3,00 US-Dollar. Aufgrund der vorgenommenen Analyse habe man sich dazu entschieden, weiterhin den Kauf der Aktie zu empfehlen.



Agentur : Aktiencheck.de

[Sstocktrader]

Psst nicht zu laut.

Andrx hat auf Basis der `02 Gewinne ein KGV von 21.
Bei einem Gewinnwachstum von ca. 100% und einem Umsatzwachstum von ca. 38 %.


MfG Sstocktrader... .

[Sstocktrader]

[Quelle der Zahlen] Yahoo! Finance

[Strand]

Du hast recht! Es könnte jemand aufmerksam werden:-) Aber schon komisch, das sich niemand für die Aktie interessiert.

[Strand]

Andrx Should Gain -- With or Without Prilosec
By Evelyn Ellison Twitchell

I n pharmaceutical circles, Prilosec is the six-billion-dollar baby.

The ulcer medicine, made by U.K. behemoth AstraZeneca , is the world`s biggest selling drug, with about $6.3 billion in sales last year.

But the main patent covering the drug expires in October, and hopes that a generic version of the drug will come to market soon gave a nice boost to the shares of Andrx Group last week.

Andrx stands to gain 180 days of market exclusivity for the first generic version of the drug, which would give it a good head start on competitors.

Andrx`s stock surged 11% last Friday after AstraZeneca said it would not list two new Prilosec-related patents in the Food and Drug Administration`s Orange Book. Listing those patents could have created new legal hurdles for Andrx.

AstraZeneca still has at least seven other patents on Prilosec (some of which expire as late as 2007), and the companies plan to take the matter to court this fall.

But Andrx`s earnings growth is accelerating, even without generic Prilosec, some fans of the stock contend.

The company is benefiting from a recent acquisition. It has a deep pipeline of generics, and it`s beginning to get into brand-name pharmaceuticals, which have higher margins than generics do.

"The base business is going to be growing substantially over the next four or five years," argues Jon Stephenson, an analyst at State Street Research & Management, which owns roughly 780,000 shares of the stock.

Andrx, based in Davie, Fla., makes several generic drugs, including the generic version of the blood pressure medication, Cardizem CD. The company, whose market capitalization is about $4.7 billion, generated $514 million in sales last year.

Andrx got a good deal when it acquired Armstrong Pharmaceuticals in March for $18 million in cash. It sold about $20 million of Armstrong`s albuterol, used in inhalers for asthma patients, the very next quarter, says Gregory Gilbert, an analyst at Merrill Lynch.

Every $5 million in albuterol that Andrx sells adds about two cents to its bottom line, estimates Elliot Wilbur, an analyst at CIBC World Markets.

"Generic albuterol has been a home run," Gilbert agrees.

Andrx also has acquired some small brand-name drugs. In January, it bought CTEX Pharmaceuticals, which gave it about 100 salespeople and some small cough and cold drugs. Then, in June, it bought another cold product line, Extex, and the marketing rights to Procet.

Altogether, these products should add about $40 million to $45 million to Andrx`s sales this year, Stephenson says.

Andrx will use the profits to boost its salesforce to 500 people ahead of the launch of its first internally developed brand-name drug, the cholesterol-lowering agent, Altocor, Andrx President Elliot Hahn tells Barron`s Online.

Meanwhile, Andrx`s generic pipeline is almost bursting.

Besides Prilosec, Andrx has filed 14 potential generic drugs with the FDA. And it expects to get 180-day exclusivity on several of those, including a generic version of the antidepressant, Wellbutrin SR.

Wellbutrin SR alone could produce some $80 million in sales and 42 cents a share in earnings during its first 12 months on the market, says Katherine Breedis, an analyst at Goldman Sachs.

The bottom line: Andrx`s quarterly earnings power should grow to roughly 50 cents a share, from 35 cents now -- without generic Prilosec, Wilbur predicts.

"The underlying earnings power of the company`s base business is accelerating," he concludes.

As for Prilosec, AstraZeneca still may list a third patent on the drug, which could cause up to a 30-month delay in the launch of Andrx`s generic. But even if it doesn`t, AstraZeneca will fight like the dickens to keep its franchise under patent protection.

But courts have tended to support generic drug manufacturers in similar cases. Most analysts who spoke to Barron`s Online expect generic Prilosec to launch during the first half of 2002, at the latest.

Stephenson believes Andrx could capture about $450 million in revenue from generic Prilosec in its first year on the market -- nearly doubling the company`s 2000 revenue.

At 65.23 late Thursday afternoon, Andrx changed hands at 44 times the $1.48 per share the company is expected to earn this year.

But the stock is trading at a more reasonable 22x the $2.98 per share Wall Street estimates the company will earn in 2002, according to Thomson Financial/First Call.

Even assuming it doesn`t release generic Prilosec next year, Andrx could earn around $2.00 per share in 2002, some analysts say.

That means it`s selling for 33x projected 2002 earnings, about in line with its expected earnings growth for next year -- not counting generic Prilosec.

One yellow flag: Since May, several officers and directors have sold lots of shares in Andrx. CEO Alan Cohen has personally sold nearly $90 million in stock during that time, about 25% of his holdings, according to Thomson Financial/Baseline.

Gale Blackburn, Andrx`s director of investor relations, says Cohen used the proceeds to buy the Florida Panthers National Hockey League team, and he brought in other Andrx officers as investors, too. In addition, Cohen has announced plans to retire soon.

And certainly, Andrx stock will be volatile as litigation proceeds this fall. It also would no doubt be pressured if generic Prilosec`s launch were delayed beyond the first half of 2002.

But the bulls think that over time the rest of its business is strong enough to compensate for that -- which could make Andrx an even better bet.

[Strand]

Monday August 20, 2:27 pm Eastern Time
Press Release
SOURCE: Andrx Corporation


Andrx Ranks No. 4 on Fortune`s List of Fastest-Growing Companies



FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Aug. 20, 2001--Andrx Corporation -- Andrx Group (Nasdaq:ADRX - news) today announced that Fortune magazine ranked the Company fourth on its September 3, 2001, annual list of 100 Fastest-Growing Companies.

The list of America`s Fastest Growing Companies was compiled by Zacks Investment Research. Its final order was derived from the sum of the rankings of growth in revenues, EPS, and total stock market return over three years. To qualify for the list, companies had to be based in the U.S., be publicly traded for at least three years, and have revenue and market capitalizations of at least $50 million. At the minimum, firms had to show 30% annual growth over three years in revenue and EPS, and positive earnings in the latest quarter and for the last four combined.

Commenting on this recognition, Elliot F. Hahn, Ph.D., President of Andrx, said: ``It is an honor to be acknowledged by Fortune which we credit to the hard work and efforts of every Andrx employee.``

About Andrx

Andrx Corporation, through its Andrx Group (Nasdaq:ADRX - news), is engaged in the formulation and commercialization of oral controlled-release pharmaceuticals utilizing its proprietary drug delivery technologies. In its ANDA program, Andrx is developing generic versions of selected high sales volume controlled-release brand name pharmaceuticals. In its NDA program, Andrx is developing its own brand name formulations of certain existing drugs that it believes may be improved by the application of Andrx`s drug delivery technologies. Andrx also markets and distributes pharmaceutical products manufactured by third parties. Through Andrx Corporation`s Cybear Group (Nasdaq:CYBA - news), Andrx Corporation intends to use the Internet to improve the efficiency of clinical, administrative and communications tasks in the healthcare industry -- while addressing the healthcare industry`s critical need for secure and reliable transmission of information. Cybear also includes the Cybearclub joint venture with Andrx, which distributes healthcare products to physicians through the Internet.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as ``may,`` ``will,`` ``to,`` ``expect,`` ``believe,`` ``anticipate,`` ``intend,`` ``could,`` ``would,`` ``estimate,`` or ``continue`` or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those risks and uncertainties detailed in the Company`s filings with the Securities and Exchange Commission.

This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com


--------------------------------------------------------------------------------
Contact:

Andrx Corporation, Fort Lauderdale
Gale A. Blackburn, 954/217-4344
Email: [e-mail]

[volkeracho]

ich beobachte andrx schon eine weile und habe mir bei 72€ paar ins depot gelegt. das einzige was mich an der aktie stört, sind die geringen umsätze in deutschland.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Aug. 20, 2001--Andrx
Corporation -- Andrx Group (Nasdaq:ADRX) today announced that Fortune magazine ranked the Company fourth on its September 3, 2001, annual list of 100 Fastest-Growing Companies.
The list of America`s Fastest Growing Companies was compiled by Zacks Investment Research. Its final order was derived from the sum of the rankings of growth in revenues, EPS, and total stock market return over three years. To qualify for the list, companies had to be based
in the U.S., be publicly traded for at least three years, and have revenue and market capitalizations of at least $50 million. At the minimum, firms had to show 30% annual growth over three years in revenue and EPS, and positive earnings in the latest quarter and for the last four combined.

Commenting on this recognition, Elliot F. Hahn, Ph.D., President of Andrx, said: "It is an honor to be acknowledged by Fortune which we credit to the hard work and efforts of every Andrx employee."

About Andrx

Andrx Corporation, through its Andrx Group (Nasdaq:ADRX), is
engaged in the formulation and commercialization of oral
controlled-release pharmaceuticals utilizing its proprietary drug delivery technologies. In its ANDA program, Andrx is developing generic versions of selected high sales volume controlled-release brand name pharmaceuticals. In its NDA program, Andrx is developing
its own brand name formulations of certain existing drugs that it believes may be improved by the application of Andrx`s drug delivery technologies. Andrx also markets and distributes pharmaceutical products manufactured by third parties. Through Andrx Corporation`s Cybear Group (Nasdaq:CYBA), Andrx Corporation intends to use the
Internet to improve the efficiency of clinical, administrative and communications tasks in the healthcare industry -- while addressing the healthcare industry`s critical need for secure and reliable
transmission of information. Cybear also includes the Cybearclub joint venture with Andrx, which distributes healthcare products to physicians through the Internet.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking
statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "believe," "anticipate,"
"intend," "could," "would," "estimate," or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all
forward-looking statements involve risks and uncertainties, including those risks and uncertainties detailed in the Company`s filings with the Securities and Exchange Commission.

This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com

--30--jd/mi*

CONTACT: Andrx Corporation, Fort Lauderdale
Gale A. Blackburn, 954/217-4344
Email: [e-mail]

[Strand]

Andrx Corporation (NASD)
Sector: Healthcare Industry: Biotechnology & Drugs

Ownership Summary
% Shares Owned: 59 Price Range Quarter: $55 - $94.25
% Change in Ownership: 11.46 # New Buyers: 33
# Institutions: 167 # Closed Positions: 15
Total Shares Held: 41,270,226
3 Mo. Shares Purchased: 9,067,410 # Buyers: 107
3 Mo. Shares Sold: (4,822,866) # Sellers 57
3 Mo. Net Change: 4,244,544 # Net Buyers: 50




Top Institutional Holders
Institution Name Shares Held Position Value (000) % Shs. Out. Portfolio Date
JANUS CAPITAL MGMT 5,606,395 $431,692.42 8.02% 6/30/2001
PUTNAM INVESTMENT MGMT 4,430,648 $341,159.90 6.34% 6/30/2001
TCW GROUP 3,863,888 $297,519.38 5.53% 6/30/2001
FIDELITY MGMT & RESEARCH CO 3,487,830 $268,562.91 4.99% 6/30/2001
CAPITAL RESEARCH & MGMT CO 2,020,000 $155,540 2.89% 6/30/2001
INVESCO FUNDS GROUP (DENVER) 1,584,545 $122,009.97 2.27% 6/30/2001
NICHOLAS APPLEGATE CAPITAL MGMT 1,356,260 $104,432.02 1.94% 6/30/2001
MORGAN STANLEY 1,099,126 $84,632.70 1.57% 6/30/2001
MASSACHUSETTS FINANCIAL SERVICES 989,270 $76,173.79 1.41% 6/30/2001
DRESDNER RCM GLOBAL INVESTORS (SAN FRANCISCO) 855,746 $65,892.44 1.22% 6/30/2001
FRIESS ASSOCIATES 800,000 $61,600 1.14% 6/30/2001
STATE STREET RESEARCH & MGMT/METROPOLITAN RESEARCH 781,575 $60,181.28 1.12% 6/30/2001
SMITH BARNEY ASSET MGMT 604,463 $46,543.65 0.86% 6/30/2001
AIM MGMT 586,863 $45,188.45 0.84% 6/30/2001
BARCLAYS GLOBAL INVESTORS INTL 558,857 $43,031.99 0.80% 6/30/2001

[volkeracho]

23.08.2001
Andrx "Market Outperformer"
Goldman Sachs

Rating-Update:

Die Analysten der Investmentbank Goldman Sachs stufen die Aktie von Andrx (WKN 565755) unverändert mit "Market Outperformer" ein.


---------

23.08.2001
Andrx "buy"
Bear Stearns

Rating-Update:

Die Analysten vom Investmenthaus Bear Stearns stufen die Aktie von Andrx (WKN 565755) unverändert mit "buy" ein. Das Kursziel wird mit 75 US-Dollar angegeben.



quelle: aktiencheck.de

[volkeracho]

BW2141 AUG 28,2001 5:29 PACIFIC 08:29 EASTERN


( BW)(FL-ANDRX)(ADRX) Andrx Announces Retirement of Chief Scientific
Officer

Business Editors/Health & Medical Writers

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Aug. 28, 2001--Andrx
Corporation -- Andrx Group (Nasdaq:ADRX) today announced that
Chih-Ming Chen, Ph.D. has resigned from his positions as the Company`s
Chief Scientific Officer and as President of Andrx Pharmaceuticals,
Inc. effective immediately. Dr. Chen will remain as Co-Chairman of the
Andrx Board of Directors and will continue to work as a consultant to
the Company.
Alan P. Cohen, Andrx`s Co-Chairman and Chief Executive Officer,
commented: "Chih-Ming`s contributions to Andrx`s success cannot be
overstated, and we will miss him. Yet, having announced my own
intention to retire some months ago, I understand and respect
Chih-Ming`s desire to pursue other interests. And, while I am
confident Chih-Ming has solidified our scientific team, his continued
involvement with Andrx will better ensure the smooth continuation of
our development efforts."
Dr. Chen stated, "We have successfully recruited and built a
strong scientific team at Andrx over the past few years and many of
the projects I led are nearing completion. I am confident that these
projects will continue without interruption and that Andrx will move
to the next level of success. I will never forget my colleagues and
will continue to support their hard work as a Board member and
consultant to the Company."
During Dr. Chen`s tenure, Andrx built a team of over 125
scientists, including 32 Ph.D.s and 8 M.D.s, and presently has 17
abbreviated new drug applications (ANDAs) and a new drug application
(NDA) on file with the FDA. Included in these filings are generic
versions of Prilosec(R), Tiazac(R), Wellbutrin SR(R), Zyban(R),
Naprelan(R), and K Dur(R) as well as Altocor(TM), the Company`s first
brand drug, which Andrx hopes to be in a position to launch in the
next twelve months.
Until a replacement can be found, Scott Lodin, Andrx`s Executive
Vice President and General Counsel, will also assume the position of
President of Andrx Pharmaceuticals, Inc.

About Andrx

Andrx Corporation, through its Andrx Group (Nasdaq:ADRX), is
engaged in the formulation and commercialization of oral
controlled-release pharmaceuticals utilizing its proprietary drug
delivery technologies. In its ANDA program, Andrx is developing
generic versions of selected high sales volume controlled-release
brand name pharmaceuticals. In its NDA program, Andrx is developing
its own brand name formulations of certain existing drugs that it
believes may be improved by the application of Andrx`s drug delivery
technologies. Andrx also markets and distributes pharmaceutical
products manufactured by third parties. Through Andrx Corporation`s
Cybear Group (Nasdaq:CYBA), Andrx Corporation intends to use the
Internet to improve the efficiency of clinical, administrative and
communications tasks in the healthcare industry -- while addressing
the healthcare industry`s critical need for secure and reliable
transmission of information. Cybear also includes the Cybearclub joint
venture with Andrx, which distributes healthcare products to
physicians through the Internet.

Forward-looking statements (statements which are not historical
facts) in this release are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. For this
purpose, any statements contained in this report that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the generality of the foregoing, words
such as "may," "will," "to," "expect," "believe," "anticipate,"
"intend," "could," "would," "estimate," or "continue" or the negative
or other variations thereof or comparable terminology are intended to
identify forward-looking statements. Investors are cautioned that all
forward-looking statements involve risk and uncertainties, including
those risks and uncertainties detailed in the Company`s filings with
the Securities and Exchange Commission.

This release and additional information about Andrx Corporation
are also available on the Internet at: http://www.andrx.com.

--30--dw/mi*

CONTACT: Andrx Corporation, Davie, Fla.
Elliot F. Hahn, Ph.D., 954/584-0300
http://www.andrx.com

[Strand]

Tuesday October 2, 8:51 am Eastern Time
Press Release
SOURCE: Andrx Corporation
Andrx Joins Nasdaq-100 Index
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Oct. 2, 2001--Andrx Group (Nasdaq:ADRX - news), a member of the Andrx Corporation, today announced that it will be added to the Nasdaq-100 Index® effective with the opening of the stock market on Thursday, October 4, 2001. The Index, which crosses major industry groups, includes 100 of the Nasdaq Exchange`s largest and most active non-financial companies based on market capitalization.

``We are proud to be added to the Nasdaq-100 Index,`` said Elliot F. Hahn, Ph.D., President of Andrx. ``Joining the Index will further heighten our Company`s visibility, and we are pleased to be part of this prestigious group.``

Andrx Group will also be included in the Nasdaq-100 Index Tracking Stock (SM) (Amex:QQQ - news) which represents ownership in the Nasdaq-100 Trust. The Trust holds a portfolio of equity securities that compose the Nasdaq-100 Index and, according to the Nasdaq Exchange, aims to provide investment results that generally correspond with its performance.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as ``may,`` ``will,`` ``to,`` ``expect,`` ``believe,`` ``anticipate,`` ``intend,`` ``could,`` ``would,`` ``estimate,`` or ``continue`` or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including those risks and uncertainties detailed in the Company`s filings with the Securities and Exchange Commission.

Andrx Corporation is a specialty pharmaceutical company engaged in the formulation and commercialization of oral controlled-release generic and brand pharmaceuticals utilizing its proprietary drug delivery technologies.

This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com

[RandomGambler1]

Last Trade
4:00PM · 75.07$ Change +3.17$ (+4.41%)

Und nicht vergessen : Jetzt im Nasdaq 100 Index !!

Specialty pharmaceuticals firm Andrx will take the spot occupied by Excite@Home , which filed for bankruptcy protection last Friday and is now halted until the company provides Nasdaq with "additional information." Also on Thursday, biotech concern Gilead Sciences will replace Exodus Communications, the beleaguered Web hosting company....

[caasa]

..kann mir einer sagen, warum Andrx heute so einen abgang gemacht hat ?
danke, freundlicher gruß

[puhvogel]

8:05AM Andrx (ADRX) 75.07: Company says that for the first time, the FDA has advised ADRX that final marketing approval for ANDA (the generic version of Prilosec) may be delayed due to issues related to omeprazole that were raised by AstroZeneca (AZN) and aai Pharma (AAII); news is negative for ADRX but positive for AZN and AAII.

[caasa]

@puhvogel

danke ! (m... ..)

[hugo_b]

NEW YORK, Nov 16 (Reuters) - Andrx Group (NasdaqNM:ADRX - news) said on Friday U.S. regulators approved its bid to market a generic form of Prilosec, an ulcer medication and the world`s biggest- selling drug.



Fort Lauderdale, Florida-based Andrx said the U.S. Food and Drug Administration said Andrx could sell its Omeprazole drug in three different dosages. It said the products` launch are on hold because of patent litigation.

Andrx`s shares jumped 7.5 percent to $68.21 in after hours trading on the Instinet electronic trading system from a close of $63.45 on Nasdaq.

Prilosec, with more than $4 billion in sales in 2000, is sold in the United States by the Anglo-Swedish drug group AstraZeneca Plc (quote from Yahoo! UK & Ireland: AZN.L). Prilosec treats heartburn and ulcers.

AstraZeneca`s main U.S. patent on the drug expired on Oct. 5, but the company is fighting generic drugmakers like Andrx, claiming several of its patents relating to Prilosec extend U.S. market exclusivity for years to come.

A trial of those patent claims is set to begin early next month in the U.S. District Court for the Southern District of New York.

``Andrx is eagerly awaiting the December 6 start of the trial,`` said Elliot Hahn, Andrx`s chief executive. ``Andrx wants to be in a position to determine whether it commences marketing of this important drug as soon as possible.``

Andrx said the FDA awarded it sole marketing exclusivity rights for its 40 mg strength product and joint exclusivity rights to its 10 mg and 20 mg products with Genpharm Inc.

Die Nachricht bringt den Generikahersteller Andrx voran. Die US-Gesundheitsbehörde FDA hat das Andrx-Nachahmerprodukt zu AstraZenecas Medikament Prilosec zur Vermarktung zugelassen. Prilosec wird gegen Magengeschwüre eingesetzt und ist mit einem Jahresumsatz von über 4 Milliarden US-Dollar eines der meist verkauften Medikamente in den USA. Allerdings ist noch ein Rechtsstreit mit AstraZenaca anhängig, der den Verkauf durch Andrx verzögert. Der Prozess beginnt Anfang Dezember. Hier stehen die Chancen für Andrx allerdings gut. Die Meldung wird den Andrx-Kurs kurzfristig beflügeln. http://www.sharper.de/sharperweb/fn/sharp/SH/0/sfn/buildshar…

Gruß hugo

[volkeracho]

21.11.2001
Andrx empfehlenswert
Aktienservice Research

Die Analysten von Aktienservice Research empfehlen derzeit dem Anleger die Aktien von Andrx (WKN 565755).

Mit dem Magengeschwür-Medikament Omeprazole, für das das Biotechnologieunternehmen Andrx am letzten Freitag die Zulassung der US-Gesundheitsbehörde FDA erhalten habe, adressiere das Unternehmen einen milliardenschweren Markt. So erziele der Hauptkonkurrent Astra Zeneca mit einem vergleichbaren Markt über sechs Milliarden US-Dollar p.a.. Vor diesem Hintergrund gehe Aktienservice Research davon aus, dass bei Andrx im kommenden Jahr eine sprunghafte Verbesserung von Umsatz und Ergebnis einsetzen werde.

Daneben agiere das Unternehmen taktisch sehr geschickt beim Unterlaufen des Patentschutzes bzw. bei der Entwicklung und Kopie von Medikamenten mit Blockbusterpotenzial. In Anbetracht der gefüllten Produkt- und Projektpipeline des Unternehmens erwarte Aktienservice Research in den nächsten zwölf Monaten einen weiterhin sehr positiven Newsflow.

Überhaupt halte Aktienservice Research Andrx fundamental für attraktiv bewertet. Das Papier sei auf Basis der EPS-Prognosen von Aktienservice Research mit einem 02e-KGV von 23 sehr günstig bewertet. Unter der Maßgabe eines adäquaten Risikomanagements halte Aktienservice Research eine Investition in Andrx für den chancenorientierten Investor für empfehlenswert.

Die Analysten von Aktienservice Research halten die alten Höchststände im nächsten Jahr wieder für erreichbar.